Nuvation Bio's safusidenib shows 81.5% clinical benefit rate in Phase 2 glioma study
NUVB•Nuvation Bio reported an 81.5% clinical benefit rate for safusidenib in a Phase 2 study of previously untreated grade 2 IDH1-mutant glioma. Updated findings showed sustained tumor shrinkage and durable disease control.
1. Updated Phase 2 findings
Nuvation Bio presented updated safusidenib results at the Society for Neuro-Oncology annual meeting on Nov. 16, 2026. The study reported an 81.5% clinical benefit rate in previously untreated grade 2 IDH1-mutant glioma, with sustained tumor shrinkage and durable disease control.
2. Safety and next stage
The company said safety remained manageable, with no new safety signals and side effects mostly low-grade, though some patients discontinued treatment. Safusidenib is advancing through the pivotal Phase 3 SIGMA study following FDA Fast Track designation in August 2026.




